Last reviewed · How we verify

Standard of Care: Docetaxel

H. Lee Moffitt Cancer Center and Research Institute · FDA-approved active Small molecule Quality 2/100

Standard of Care: Docetaxel is a Taxane; microtubule stabilizer Small molecule drug developed by H. Lee Moffitt Cancer Center and Research Institute. It is currently FDA-approved for Metastatic breast cancer, Non-small cell lung cancer, Prostate cancer. Also known as: Taxotere®.

Docetaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in cancer cells.

Docetaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in cancer cells. Used for Metastatic breast cancer, Non-small cell lung cancer, Prostate cancer.

At a glance

Generic nameStandard of Care: Docetaxel
Also known asTaxotere®
SponsorH. Lee Moffitt Cancer Center and Research Institute
Drug classTaxane; microtubule stabilizer
Targetβ-tubulin
ModalitySmall molecule
Therapeutic areaOncology
PhaseFDA-approved

Mechanism of action

Docetaxel is a taxane that binds to the β-tubulin subunit of microtubules and prevents their disassembly, leading to stabilization of the microtubule structure. This disrupts normal cell division by arresting cells in the G2/M phase of the cell cycle, ultimately triggering apoptosis. It is effective against rapidly dividing cancer cells across multiple tumor types.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Standard of Care: Docetaxel

What is Standard of Care: Docetaxel?

Standard of Care: Docetaxel is a Taxane; microtubule stabilizer drug developed by H. Lee Moffitt Cancer Center and Research Institute, indicated for Metastatic breast cancer, Non-small cell lung cancer, Prostate cancer.

How does Standard of Care: Docetaxel work?

Docetaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in cancer cells.

What is Standard of Care: Docetaxel used for?

Standard of Care: Docetaxel is indicated for Metastatic breast cancer, Non-small cell lung cancer, Prostate cancer, Gastric adenocarcinoma, Head and neck cancer.

Who makes Standard of Care: Docetaxel?

Standard of Care: Docetaxel is developed and marketed by H. Lee Moffitt Cancer Center and Research Institute (see full H. Lee Moffitt Cancer Center and Research Institute pipeline at /company/h-lee-moffitt-cancer-center-and-research-institute).

Is Standard of Care: Docetaxel also known as anything else?

Standard of Care: Docetaxel is also known as Taxotere®.

What drug class is Standard of Care: Docetaxel in?

Standard of Care: Docetaxel belongs to the Taxane; microtubule stabilizer class. See all Taxane; microtubule stabilizer drugs at /class/taxane-microtubule-stabilizer.

What development phase is Standard of Care: Docetaxel in?

Standard of Care: Docetaxel is FDA-approved (marketed).

What are the side effects of Standard of Care: Docetaxel?

Common side effects of Standard of Care: Docetaxel include Neutropenia, Anemia, Thrombocytopenia, Peripheral neuropathy, Alopecia, Nausea and vomiting.

What does Standard of Care: Docetaxel target?

Standard of Care: Docetaxel targets β-tubulin and is a Taxane; microtubule stabilizer.

Related